Mantle Cell Lymphoma

Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according to study results.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab maintenance for young patients with mantle cell lymphoma.

In this video, Jakub Svoboda, MD, discusses the results of a large real-world study on brexu-cel for mantle cell lymphoma, which were presented at ASCO Annual Meeting.

In this video, Jakub Svoboda, MD, discusses an update on pirtobrutinib, which was recently approved for relapsing mantle cell lymphoma that has been previously treated with Bruton tyrosine kinase inhibitors.

In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.

In this video, Michael Choi, MD, discusses updated data on the results of pirtobrutinib treatments on mantle lymphocytic leukemia, presented at ASCO Annual Meeting.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses mantle cell lymphoma research presented at ASCO Annual Meeting.

Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.